6th International Bioaerosols Conference - September 6 – 9, 2011
Does Reversibility of Neurobehavioral Dysfunction have Diagnostic and Possible Therapeutic Use in Mold/Mycotoxin Exposed Patients?
Kaye H. Kilburn, M.D.
Five Points led me to suggest to patients to try anti-inflammatory redox agents to treat
neurological inflammation from chemicals in molds and mycotoxins. 1) Functions of the human brain could be measured: balance, reaction time, color, visual fields, grip strength and hearing complement psychological tests. 2) Total abnormalities quantify losses and recoveries. 3) neurologic inflammation-oxidation coincided with irritation of skin, nose and upper airway and lung. 4) The blood brain barrier is breached by the olfactory nerve to deliver chemicals. 5) Human brain has the same timing as animal models.
Methods
The first 10 patients received glutathione intranasally (IN) at 100 mg/ml, luminol 10
mg/ml or both at varied doses and frequencies and effects measured at 24, 48, and 72 hours. There were no adverse effects. Cells in culture and rodent models showed effects at 1.5 to 3 hours. The second series of 20 patients, received 10 times larger luminol doses IN and showed improved measured effects in 1.5 to 3.0 hours. I used regression analysis to search for patterns of improvement and time sequence from exposure agents, duration of symptoms, to age, education and gender. Then I compared their reversibility to that of chemically exposed patients.
Results
The 10 low dose luminol patients who were 19 to 61 years of age, mean 42.4, education level 10 to 20, mean 15.7 years, had 7-14 initial abnormalities, averaged 9.1 and decreased to 4.3 (p < 0.01). No additional benefit was measured from glutathione or vitamin C.
One non responder had grand mal seizures, one had chorioathetosis, and the third had high
dose H2S exposure while confined for 3 hours in an air conditioned tractor cab.
The 20 high dose luminol patients were 35 to 69 years of age, mean 49.4 years, educational
level 11 to 20, mean 13.4 years, and had 4 to 21 abnormalities and averaged 9.6. After
receiving 70 to 100 mg/ml IN, abnormalities decreased to 2.9 (p < 0.001) in 1.5 to 3 hours and 24 hours with repeated doses. Balance improved, to normal sway speeds in most patients. Verbal recall, problem solving, and long term memory usually improved. The 20 patients reported/observed improved mental clarity (absence of brain fog) decreased headache, decreased tremors, decreased leg pain, improved steadiness, and improved recall in 90 to 180 minutes after an intranasal dose of luminol. Patients exposed to mold/mycotoxins improved to be closer to predicted performance when compared to ten patients exposed to chlorine 2, ethylene glycol 2, pyrethroids 2, chlordane 1, formaldehyde 1, arsenic 1, and mercury 1.
Conclusion
A redox agent given intranasally improved neurobehavioral functions including
balance, problem solving, grip strength and color discrimination in mold/mycotoxins exposed patients, after 30 days of treatment, stopping these agents returned to pretreatment levels in 2 days. Redox treatment with intranasal agents deserves further evaluation to determine degree of improvement and if it persists after treatment is stopped.